| Ytd | -30.32% | |
| 1y | -3.54% |
| Open | 4.19 | Prev Close | 4.20 | Low | 4.08 | High | 4.47 | Mkt Cap | 52.26M |
| Vol | 73.34K | Avg Vol | 87.53K | EPS | -2.82 | P/E | -1.45 | Forward P/E | -1.34 |
| Beta | 0.41 | Short Ratio | 1.90 | Inst. Own | 12.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 5.53 | 200-d Avg | 6.15 | 1yr Est | 45.17 |
CLNN News
SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that man
Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estima
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pa
Clene NASDAQ: CLNN said it is preparing to submit a new drug application, or NDA, in early fourth qu
SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidia
Clene (CLNN) appears to have found support after losing some value lately, as indicated by the forma
Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estim
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® unde
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiar
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiar
Clene Inc. (NASDAQ:CLNN) shares are up 6.68% on Monday as the company is filing for accelerated appr
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 7,748 shares of
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,374 shares of
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 25,040 shares of
In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidia
Ventyx Biosciences (NASDAQ: VTYX - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are b
Clene Inc. (NASDAQ: CLNN - Get Free Report) has been assigned an average rating of "Moderate Buy" fr
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidia
On Tuesday, 838 companies hit new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after
Before 10 a.m. ET on Tuesday, 128 companies hit new 52-week highs.